Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C1EO
|
|||
| Former ID |
DIB009303
|
|||
| Drug Name |
Melanoma vaccine (ALVAC)
|
|||
| Synonyms |
Melanoma vaccine (ALVAC), sanofi pasteur; Melanoma vaccine (gp100/MAGE-1/MAGE-3/MART-1/NY-ESO-1, ALVAC), sanofi pasteur
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Discontinued in Phase 2 | [1] | |
| Company |
Sanofi Pasteur
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cancer/testis antigen 1 (NY-ESO-1) | Target Info | . | [2] |
| MART-1 melanoma antigen (MLANA) | Target Info | . | [2] | |
| Melanocytes lineage-specific antigen GP100 (PMEL) | Target Info | . | [2] | |
| Melanoma-associated antigen 1 (MAGEA1) | Target Info | . | [2] | |
| Melanoma-associated antigen 3 (MAGEA3) | Target Info | . | [2] | |
| WikiPathways | Notch Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014153) | |||
| REF 2 | Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma. J Immunother. 2010 Oct;33(8):743-58. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.